Filing Analysis
IRIDEX Corporation filed an 8-K to furnish its press release regarding financial results for the second fiscal quarter ended July 4, 2026. The filing is a standard earnings announcement and does not contain material non-public information or structural changes.
📋 Key Facts
- Reporting period: Second fiscal quarter ended July 4, 2026.
- Filing date: August 18, 2026.
- The filing includes Exhibit 99.1, which is the press release containing the financial results.
- The information is furnished under Item 2.02 and is not considered 'filed' for purposes of Section 18 of the Exchange Act.
IRIDEX Corporation reports highly irregular voting results from its 2026 Annual Meeting, alleging a 'stealth proxy campaign' orchestrated by at least one sitting director to undermine fellow board members. The company claims these actions likely violated fiduciary duties and federal securities laws (SEC Rule 13D).
🚩 Red Flags
- Alleged 'stealth proxy campaign' by an internal director against fellow board members.
- Potential violations of federal securities laws (SEC Rule 13D, 14a-3, 14a-6).
- Significant breach of fiduciary duties (Duty of Candor and Duty of Loyalty) alleged by the Board.
- Internal governance crisis involving potential undisclosed 'groups' influencing company control.
- Complex related-party dynamics involving Novel Inspiration International Co., Ltd and Director William Moore.
📋 Key Facts
- The 2026 Annual Meeting was adjourned from June 12, 2026, to July 10, 2026, to investigate divergent vote tallies for directors Scott Shuda and Beverly Huss.
- All five director nominees were re-elected under a plurality voting standard despite significant 'withhold' votes.
- The Board alleges a subset of stockholders acted in concert as an undisclosed 'group' to influence election results.
- The company claims the campaign likely violated SEC Rules 14a-3 and 14a-6 regarding proxy solicitations without public disclosure.
- The filing notes significant historical context involving Series B Preferred Stock issued to Novel Inspiration International Co., Ltd ('Novel') and associated PIK notes.
Iridex Corporation announced that its 2026 annual meeting of stockholders, originally scheduled for June 12, 2026, was adjourned without conducting any business. The meeting has been rescheduled for July 10, 2026.
🚩 Red Flags
- Adjournment of an annual meeting without conducting business often indicates a failure to reach a quorum, which can be a sign of shareholder apathy or fragmented ownership in micro-cap companies.
📋 Key Facts
- Annual meeting date originally set for June 12, 2026.
- Meeting adjourned without business conducted.
- New meeting date scheduled for July 10, 2026, at 8:00 a.m. PT.
- Record date for voting remains April 17, 2026.
- Previously submitted proxies remain valid.
IRIDEX Corporation filed a Form 8-K to report its financial results for the first fiscal quarter ended April 4, 2026, which were released in a press release dated May 19, 2026.
📋 Key Facts
- IRIDEX Corporation reported its first fiscal quarter financial results for the period ended April 4, 2026.
- The press release was furnished as Exhibit 99.1 under Item 2.02.
- The filing was signed by Romeo R. Dizon, Chief Financial Officer, on May 19, 2026.
IRIDEX Corporation announced its financial results for the fourth fiscal quarter ended January 3, 2026, via a press release furnished with the SEC. This is a routine quarterly earnings disclosure under Item 2.02.
📋 Key Facts
- Financial results reported for the fourth fiscal quarter ended January 3, 2026.
- The report was filed on March 26, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the full press release detailing the financial performance.
IRIDEX Corporation entered into a new 90-month lease agreement for a 30,784 square foot facility in San Jose, California, which will serve as its new corporate headquarters starting July 2026.
📋 Key Facts
- Lease agreement signed on March 9, 2026, with SFIII Hellyer, LLC for 30,784 square feet of office space.
- The 90-month term is expected to commence on July 1, 2026.
- Initial annual minimum rent is approximately $646,464, increasing to $665,857 in the second year, with 3% annual escalations thereafter.
- The agreement includes a six-month rent abatement period following the commencement date.
- The company has an option to extend the lease for an additional 60 months at market rates.
IRIDEX Corporation announced preliminary, unaudited operational and financial results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The filing serves as a placeholder to furnish the press release containing these results.
📋 Key Facts
- Reporting period: Fourth fiscal quarter and full fiscal year ended January 3, 2026.
- Announcement date: January 12, 2026.
- The filing includes preliminary, unaudited financial data via Exhibit 99.1.
IRIDEX Corporation is participating in the Sidoti Year-End Virtual Investor Conference on December 11, 2025. The company provided presentation materials as an exhibit under Regulation FD disclosure.
📋 Key Facts
- Participation in Sidoti Year-End Virtual Investor Conference on Dec 11, 2025.
- Live webcast scheduled for 10:45 a.m. ET.
- Presentation materials provided as Exhibit 99.1.
IRIDEX Corporation filed an 8-K to furnish its third fiscal quarter financial results for the period ended September 27, 2025. The filing serves as a formal announcement of the press release containing these earnings results.
📋 Key Facts
- Reporting period: Third fiscal quarter ended September 27, 2025.
- Filing date: November 11, 2025 (Reported) / November 12, 2025 (Signed).
- The filing includes Exhibit 99.1, which contains the actual financial results press release.
IRIDEX Corporation has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement of $2,500,000. This resolves the non-compliance notice issued by Nasdaq on May 14, 2025.
🚩 Red Flags
- History of delisting risk due to failure to meet minimum stockholders' equity requirements (Rule 5550(b)).
- The company was operating under a non-compliance notice for several months (May to August 2025).
📋 Key Facts
- The Company was previously in violation of Nasdaq Listing Rule 5550(b) regarding minimum stockholders' equity.
- As of August 27, 2025, the Company has satisfied the $2,500,000 minimum stockholders' equity requirement.
- Nasdaq informed the Company on August 27, 2025, that the non-compliance matter is now closed.
- The compliance status was verified based on the Form 10-Q filed for the period ended June 28, 2025.
IRIDEX Corporation filed an 8-K to furnish its second fiscal quarter financial results for the period ended June 28, 2025. The filing serves as a formal mechanism to release the earnings press release via Exhibit 99.1.
📋 Key Facts
- Reporting Period: Second fiscal quarter ended June 28, 2025.
- Filing Date: August 12, 2025.
- Content: Financial results discussed in a press release (Exhibit 99.1).
- Status: Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18.
IRIDEX Corporation held its 2025 Annual Meeting of Stockholders on June 11, 2025, where shareholders approved several key structural and governance changes. Significant outcomes included the approval of a Restated Charter that increases authorized common stock from 30M to 63.5M shares and an amendment to the equity incentive plan.
🚩 Red Flags
- Significant increase in authorized share count (from 30M to 63.5M) suggests potential future dilution.
- Approval of Nasdaq rule waivers regarding specific large-scale issuances to a single entity (Novel Inspiration International Co., Ltd.) can indicate structured financing needs or existing debt conversion complexities.
📋 Key Facts
- Annual Meeting held on June 11, 2025; quorum reached with 80.65% of common stock present.
- Stockholders approved increasing authorized common stock from 30,000,000 to 63,500,000 shares via a Restated Charter.
- Approved an increase in the 2008 Equity Incentive Plan by 1,000,000 additional shares and extended its term to June 11, 2035.
- Stockholders approved the removal of Nasdaq limitations regarding share issuances to Novel Inspiration International Co., Ltd. (Novel) for conversions/notes up to 19.99% of outstanding shares.
- Ratified BPM LLP as the independent registered public accounting firm for the fiscal year ending January 3, 2026.
IRIDEX Corporation has amended its Investor Rights Agreement with Novel Inspiration International Co., Ltd. The amendment imposes new restrictive covenants regarding the sale or disposition of company assets.
🚩 Red Flags
- Restrictive covenant: The requirement for 'unanimous consent of the board' for asset dispositions suggests significant loss of management control to an investor.
- Potential liquidity/exit constraint: Such clauses can complicate future M&A activity or strategic pivots if a single board member (likely representing the investor) disagrees.
📋 Key Facts
- Amendment No. 1 to Investor Rights Agreement executed on May 20, 2025.
- The agreement is between IRIDEX Corporation and Novel Inspiration International Co., Ltd.
- The amendment requires unanimous board consent for the sale, lease, or disposition of a substantial portion (but less than substantially all) of the Company's assets.
IRIDEX Corporation received a notice from Nasdaq for non-compliance with the minimum stockholders' equity requirement. The company plans to resolve this by seeking stockholder approval to reclassify Series B Preferred Stock as 'permanent equity'.
🚩 Red Flags
- Delisting notice from Nasdaq (non-compliance with Rule 5550(b)(1))
- Significant deficiency in stockholders' equity ($852k vs $2.5M required)
- Reliance on a single regulatory/structural fix (reclassification of preferred stock) to maintain listing status
📋 Key Facts
- Nasdaq issued a non-compliance notice on May 14, 2025.
- Stockholders' equity was reported at approximately $852,000 as of March 29, 2025, falling below the $2,500,000 requirement.
- The deficiency is primarily due to $6,000,000 in Series B Preferred Stock (sold in March 2025) being classified as 'temporary equity'.
- Company intends to submit a compliance plan by June 30, 2025.
- A proposal to amend the Certificate of Incorporation to reclassify Series B Preferred Stock as 'permanent equity' will be voted on at the annual meeting on June 11, 2025.
IRIDEX Corporation filed an 8-K to furnish its quarterly press release regarding financial results for the first fiscal quarter ended March 29, 2025.
📋 Key Facts
- Reporting period: First fiscal quarter ended March 29, 2025.
- Filing date: May 13, 2025.
- The filing consists of a press release (Exhibit 99.1) discussing results of operations and financial condition.
IRIDEX Corporation announced its preliminary, unaudited operational and financial results for the first fiscal quarter ended March 29, 2025. The filing serves as a placeholder to furnish the press release containing these results.
📋 Key Facts
- Reporting period: First fiscal quarter ended March 29, 2025.
- Announcement date: April 14, 2025.
- Results are preliminary and unaudited.
IRIDEX Corporation announced the resignation of Director Kenneth E. Ludlum, effective April 7, 2025. The departure is a direct consequence of a Rights Agreement entered into with Novel Inspiration International Co., Ltd. on March 19, 2025, which mandates a fixed Board size of five directors.
🚩 Red Flags
- Board restructuring triggered by a third-party investor agreement (Rights Agreement) suggests significant influence from Novel Inspiration International Co., Ltd.
- Loss of board seat as a condition of financing/investment often indicates shifting control or governance changes following capital injections.
📋 Key Facts
- Kenneth E. Ludlum resigned from the Board effective April 7, 2025.
- The resignation is not due to any disagreement with Company operations, policies, or practices.
- The departure was required to comply with a Rights Agreement signed on March 19, 2025, with Novel Inspiration International Co., Ltd. ('Novel').
- The Rights Agreement limits the Board of Directors size to exactly five members.
IRIDEX Corporation announced the resignation of Director Robert E. Grove effective April 2, 2025. The departure is a direct consequence of a Rights Agreement entered into with Novel Inspiration International Co., Ltd. on March 19, 2025, which mandates a fixed Board size of five directors.
🚩 Red Flags
- Board composition is being dictated by an external investor (Novel Inspiration International Co., Ltd.) via a Rights Agreement.
- The resignation was triggered by financing/investment terms rather than voluntary departure, indicating potential loss of board control or significant dilution/reorganization resulting from the 'Novel Transaction'.
📋 Key Facts
- Director Robert E. Grove resigned effective April 2, 2025.
- The resignation is not due to any disagreement regarding company operations, policies, or practices.
- The departure was required to comply with a Rights Agreement signed on March 19, 2025, with Novel Inspiration International Co., Ltd. ('Novel').
- The Rights Agreement stipulates the Board of Directors must be maintained at exactly five members.
IRIDEX Corporation filed an 8-K to furnish its press release regarding financial results for the fourth fiscal quarter ended December 28, 2024.
📋 Key Facts
- The filing is a routine announcement of quarterly earnings results (Item 2.02).
- Reporting period: Fourth fiscal quarter ended December 28, 2024.
- Filing date: March 27, 2025.
IRIDEX Corporation entered into a significant financing arrangement with Novel Inspiration International Co., Ltd. involving $4 million in convertible promissory notes and 600,000 shares of Series B Preferred Stock. The deal includes investor rights to appoint two board members and provides for up to $10 million in additional 'Growth Notes'.
🚩 Red Flags
- High-interest debt (12% per annum) being issued in the form of convertible notes.
- Interest payments are payable in Common Stock, which can lead to significant dilution for existing shareholders.
- The 'Price Floor' of $0.21 on interest payments provides a mechanism for massive equity issuance if the stock price drops.
- Investor gains significant control rights, including the right to approve certain corporate actions and appoint two board members.
📋 Key Facts
- Issued 600,000 shares of Series B Preferred Stock at $10.00 per share.
- Issued an initial convertible promissory note for $4,000,000 aggregate principal amount (Initial Note).
- The Initial Note bears a 12% annual interest rate, payable quarterly in Common Stock with a price floor of $0.21.
- Investor has the right to purchase up to $10,000,000 in additional 'Growth Notes' via three installments over three years.
- The Investor (Novel Inspiration International Co., Ltd.) gains rights to appoint two members to the Board of Directors.
- Company used proceeds from this transaction to repay a $3,330,999.99 obligation to Lind Global Asset Management IX LLC.
IRIDEX Corporation announced its preliminary, unaudited operational and financial results for the fourth fiscal quarter and full fiscal year ended December 28, 2024. The filing serves as a placeholder to furnish the press release containing these results.
📋 Key Facts
- Reporting period: Fourth fiscal quarter and full fiscal year ended December 28, 2024.
- Announcement date: January 14, 2025.
- The filing includes preliminary and unaudited financial results via Exhibit 99.1.
This 8-K/A amendment corrects the resignation date of former CEO David Bruce and provides supplemental details regarding his separation agreement. It also discloses updated compensation terms for current CEO Patrick Mercer, including a new Change in Control Severance Agreement.
🚩 Red Flags
- CEO termination and subsequent Board resignation (leadership turnover).
- Acceleration of significant equity awards (RSUs and options) for the departing CEO.
- Amendment to a previous 8-K filing suggests administrative/reporting corrections are required.
📋 Key Facts
- David Bruce was terminated as CEO on October 1, 2024, and resigned from the Board effective November 22, 2024.
- The company entered into a separation agreement with Mr. Bruce on November 11, 2024.
- Separation benefits for Mr. Bruce include a $45,000 lump sum ($20,000 for COBRA, $25,000 for other intangibles) and full acceleration of 19,913 unvested RSUs and 40,431 options.
- CEO Patrick Mercer's compensation was adjusted on November 7, 2024, to include an annual target bonus of 65% of his $360,000 base salary.
- Patrick Mercer entered into a Change in Control Severance Agreement providing for 150% of base salary if terminated without cause or upon change in control.
IRIDEX Corp announced that its current President, CEO, and COO, Patrick Mercer, has been appointed to the Company's Board of Directors, effective November 22, 2024.
📋 Key Facts
- Patrick Mercer appointed to the Board of Directors on November 22, 2024.
- Mercer currently serves as President, CEO, and COO.
- His initial term expires at the Company's 2025 annual meeting of stockholders.
- No changes were made to his existing compensatory arrangements due to this appointment.
- He will not receive additional compensation for his board service per the company's non-employee director cash compensation policy.
IRIDEX Corp announced the termination of CEO David Bruce on October 1, 2024, and his subsequent resignation from the Board. The filing also details a compensation adjustment for the current CEO, Patrick Mercer, including a new change-in-control severance agreement.
🚩 Red Flags
- Abrupt termination of the CEO (effective immediately).
- Significant acceleration of equity awards for departing executive.
- Increased severance obligations/contingent liabilities via new Change in Control agreement for current CEO.
📋 Key Facts
- CEO David Bruce was terminated effective October 1, 2024, and resigned from the Board on November 11, 2024.
- Separation package for Mr. Bruce includes a $45,000 lump sum ($20k for COBRA, $25k for intangibles).
- Full acceleration of 19,913 unvested RSUs and 40,431 options was granted to Mr. Bruce upon separation.
- CEO Patrick Mercer's compensation was adjusted: $360,000 base salary with a 65% target bonus.
- New Change in Control Severance Agreement for Patrick Mercer provides 150% of base salary if terminated without cause or during a change in control.
- Kenneth E. Ludlum appointed to the Compensation Committee on November 7, 2024.
IRIDEX Corporation filed an 8-K to announce the release of its third fiscal quarter financial results for the period ended September 28, 2024. The filing serves as a formal notice that earnings information was made public via press release.
📋 Key Facts
- Reporting date: November 12, 2024
- Fiscal period covered: Third fiscal quarter ended September 28, 2024
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Information is furnished under Item 2.02 and not 'filed' for purposes of Section 18.
IRIDEX Corp announced a significant leadership transition effective October 1, 2024. Patrick Mercer has been appointed as the new CEO and Principal Executive Officer, replacing David I. Bruce, while Scott Shuda has transitioned to Executive Chairperson.
🚩 Red Flags
- Sudden departure/transition of a sitting CEO in a micro-cap environment can sometimes signal internal friction or strategic shifts.
📋 Key Facts
- Patrick Mercer appointed as Chief Executive Officer and Principal Executive Officer effective Oct 1, 2024.
- David I. Bruce is transitioning out of the CEO role.
- Patrick Mercer will retain his current roles as President and Chief Operating Officer.
- Scott Shuda has been appointed as Executive Chairperson; no additional compensation was provided for this appointment.
IRIDEX Corporation filed a resale registration statement on Form S-3 to register shares issuable upon the conversion of a $4.2 million senior convertible promissory note and shares issued under a previous Purchase Agreement with Lind Global Asset Management IX LLC.
🚩 Red Flags
- Potential future dilution: The registration covers a significant number of potential new shares (approx. 1.7 million) that could be issued upon conversion.
- Convertible debt usage: Use of senior convertible promissory notes is often indicative of a need for immediate liquidity, common in micro-cap companies facing cash constraints.
📋 Key Facts
- Filed a resale registration statement on Form S-3 on September 5, 2024.
- The registration covers shares from a $4.2 million senior convertible promissory note dated August 7, 2024.
- Registration includes 'Note Shares' (from the Note) and 'Incentive Shares' (from an August 4, 2024 Purchase Agreement).
- If the $4.2 million Note is converted at a premium price of $2.44, it would result in approximately 1.7 million additional shares.
- No Note Shares have been issued to Lind Global Asset Management IX LLC as of the filing date.
IRIDEX Corporation closed a financing round with Lind Global Asset Management IX LLC, raising approximately $3.4 million via a convertible promissory note. The filing also includes the company's Q2 2024 financial results press release.
🚩 Red Flags
- Use of convertible promissory notes often indicates a need for immediate liquidity and can lead to future dilution for existing shareholders.
📋 Key Facts
- Closed financing with Lind Global Asset Management IX LLC (managed by The Lind Partners, LLC).
- Raised net proceeds of approximately $3.4 million.
- Financing structured as a convertible promissory note.
- The Note was previously announced in an 8-K filed on August 5, 2024.
- Company issued Q2 2024 financial results (period ended June 29, 2024).
IRIDEX Corporation entered into a securities purchase agreement with Lind Global Asset Management IX LLC for the issuance of $6,000,000 in senior convertible promissory notes. The deal includes significant dilution potential and restrictive covenants.
🚩 Red Flags
- Significant dilution: Conversion cap is 30% of outstanding shares following stockholder approval.
- Death Spiral/Downside Protection: If an Event of Default occurs, Lind can convert at the lower of current price or 80% of VWAP (subject to floor).
- Restrictive Covenants: Negative covenants include restrictions on incurring new debt and issuing other equity.
- Default Trigger: Market capitalization falling below $20,000,000 for 10 consecutive days triggers an Event of Default.
- Prepayment Penalty: Early repayment requires a premium (90% to 93.33% of principal depending on timing).
- Incentive Shares: Additional shares ($250,000 worth) are issued if the Initial Note is not repaid within 180 days.
📋 Key Facts
- Total principal amount: $4,200,000 (Initial Note) + $1,800,000 (Subsequent Note) = $6,000,000.
- Purchase price for notes: $3,500,000 and $1,500,000 respectively (discounted financing).
- Initial conversion price: $2.44 per share; Floor Price: $0.39.
- Maturity date: 24 months from issuance.
- Repayment terms include a 4% premium if paid in cash, or shares at a discount (90% of 5-day VWAP).
- The company must hold a special stockholder meeting within 120 days to obtain approval for share issuances exceeding certain thresholds.
IRIDEX Corporation is transferring its listing from the Nasdaq Global Market to the Nasdaq Capital Market due to a failure to meet minimum market value requirements. The company's market value of listed securities (MVLS) fell below the $50,000,000 threshold for 30 consecutive business days.
🚩 Red Flags
- Delisting notice/Non-compliance with Nasdaq listing rules.
- Significant drop in market capitalization (MVLS below $50M threshold).
- Downgrade from 'Global Market' to 'Capital Market' indicates reduced liquidity and prestige.
📋 Key Facts
- Received notification of non-compliance from Nasdaq on June 27, 2024.
- Failure to meet Minimum MVLS Requirement: Market value of listed securities was below $50,000,000 for 30 consecutive business days per Nasdaq Listing Rule 5450(b)(2)(A).
- Company is initiating a transfer from the Nasdaq Global Market to the Nasdaq Capital Market.
- The transfer aims to achieve compliance with continued listing requirements.
- Trading of IRIX common stock will continue on Nasdaq under the same symbol.
IRIDEX Corporation held its 2024 Annual Meeting of Stockholders on June 18, 2024. The meeting resulted in the election of five directors and the ratification of BPM LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 18, 2024, with a quorum of 65.25% (10,605,381 shares) present.
- Five directors were elected: David I. Bruce, Robert Grove, Ph.D., Beverly A. Huss, Kenneth E. Ludlum, and Scott Shuda.
- Stockholders ratified the appointment of BPM LLP as independent registered public accounting firm for fiscal year ending Dec 28, 2024.
- Advisory vote to approve executive compensation was approved by stockholders.
- Audit Committee composition modified to include Kenneth E. Ludlum (Chair), Beverly A. Huss, and Robert Grove, Ph.D.
IRIDEX Corporation announced a leadership restructuring where Patrick Mercer was appointed President while retaining his COO role. This change is intended to allow CEO David I. Bruce to focus on pursuing 'strategic alternatives' for the company.
🚩 Red Flags
- The explicit mention that the CEO is focusing on 'pursuit of the Company’s strategic alternatives' is a common euphemism in micro-cap companies for seeking a sale, merger, or restructuring due to financial/operational challenges.
📋 Key Facts
- Effective May 22, 2024, Patrick Mercer was appointed President of IRIDEX Corporation.
- Mr. Mercer will continue to serve as Chief Operating Officer (COO).
- CEO David I. Bruce will focus on pursuing 'strategic alternatives'.
- Compensation for Mr. Mercer includes a base salary increase to $360,000 and an award of 120,000 Restricted Stock Units (RSUs) vesting over three years.
IRIDEX Corporation filed an 8-K to furnish its press release regarding financial results for the first fiscal quarter ended March 30, 2024. The filing serves as a formal mechanism to provide quarterly earnings updates to the market.
📋 Key Facts
- Reporting period: First fiscal quarter ended March 30, 2024.
- Filing date: May 14, 2024.
- The filing includes Exhibit 99.1, which contains the actual financial results press release.
IRIDEX Corporation filed an 8-K to furnish its press release regarding the financial results for the fourth fiscal quarter and full fiscal year ended December 30, 2023.
📋 Key Facts
- Reporting period: Fourth fiscal quarter and fiscal year ended December 30, 2023.
- Filing date: March 26, 2024.
- The filing is a standard earnings release under Item 2.02.